AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17327245 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (three-monthly from age 15 months to 5 years)
Number of subjects: 0
Study 17327245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during pregnancy)
Number of subjects: 0
Study 17327245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three-monthly from age 15 months to 5 years)
Number of subjects: 0
Study 15713723 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (Te)
Number of subjects: 16
Study 15713723 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 16
Study 15713723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 16
Study 15713723 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human IGF‐I
Number of subjects: 16
Study 11907491 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg almotriptan
Number of subjects: 20
Study 11907491 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg almotriptan
Number of subjects: 20
Study 11907491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10446889 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients
Number of subjects: 23
Study 10446889 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study 7789897 — intervention group
Group type: EXPERIMENTAL
Intervention: VitaCuff catheter
Number of subjects: 133
Study 7789897 — intervention group
Group type: COMPARATOR
Intervention: Standard triple lumen catheters (control)
Number of subjects: 133
Study 1915205 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate-rich diet (23% energy from polyunsaturated fatty acids)
Number of subjects: 12
Study 1915205 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate-rich diet
Number of subjects: 12
Study 1915205 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid-rich diet (30% energy)
Number of subjects: 12
Study 6958474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 100 micrograms q.i.d.
Number of subjects: 40
Study 6958474 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aerosol 10 micrograms q.i.d.
Number of subjects: 40
Study 6958474 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aerosol 50 micrograms q.i.d. with Inhalet
Number of subjects: 40
Study 6958474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31871115 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (one dose prior to cisplatin CRT, followed by two doses during CRT)
Number of subjects: 40
Study 31871115 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (three doses during CRT)
Number of subjects: 40
Study 30134301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg, orally) administered the night before surgery and 2 hours before anesthesia induction
Number of subjects: 122
Study 30134301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg, orally)
Number of subjects: 122
Study 30134301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin B)
Number of subjects: 122
Study 28490565 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin (50 mg daily)
Number of subjects: 106
Study 28490565 — intervention group
Group type: COMPARATOR
Intervention: metformin (1000 mg daily)
Number of subjects: 106
Study 26062822 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Bayesian PK-guided dosing
Number of subjects: 60
Study 26062822 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing procedure
Number of subjects: 60
Study 24645687 — intervention group
Group type: EXPERIMENTAL
Intervention: double unrelated umbilical cord blood (dUCB)
Number of subjects: 0
Study 24645687 — intervention group
Group type: COMPARATOR
Intervention: HLA-haploidentical related donor bone marrow (haplo-BM)
Number of subjects: 0
Study 22811033 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training protocol
Number of subjects: 52
Study 22811033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 52
Study 19770395 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 23665
Study 19770395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 23665
Study 19770395 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 23665
Study 17195950 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 61
Study 17195950 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 61
Study 17195950 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD controls
Number of subjects: 61
Study 14698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Number of subjects: 100
Study 14698825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 100
Study 12408447 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 0
Study 12408447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus and bulgaricus
Number of subjects: 0
Study 12408447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG, Bifidobacterium longum, Enterococcus faecium SF68
Number of subjects: 0
Study 12408447 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics in general
Number of subjects: 0
Study 12408447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial recovery assessment in stools
Number of subjects: 0
Study 9566654 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement and swimming program (swimming sessions twice weekly and group physical activity once weekly, each lasting 30 minutes for 6 months)
Number of subjects: 46
Study 9566654 — intervention group
Group type: COMPARATOR
Intervention: Bobath physical therapy (30 minutes, 4 days per week)
Number of subjects: 46
Study 8594692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 102
Study 8594692 — intervention group
Group type: COMPARATOR
Intervention: Quinine infusion
Number of subjects: 102
Study 2496707 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training intervention
Number of subjects: 0
Study 2496707 — intervention group
Group type: COMPARATOR
Intervention: Lecture on 'safer sex' without skills training
Number of subjects: 0
Study 484357 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol test with expectation of hearing improvement
Number of subjects: 0
Study 484357 — intervention group
Group type: COMPARATOR
Intervention: Glycerol test with expectation of hearing deterioration
Number of subjects: 0
Study 30640726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor group (physiotherapy plus cognitive training)
Number of subjects: 58
Study 30640726 — intervention group
Group type: COMPARATOR
Intervention: Motor group (motor physiotherapy)
Number of subjects: 58
Study 28266779 — intervention group
Group type: COMPARATOR
Intervention: semaglutide
Number of subjects: 30
Study 25955225 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg) and calcitriol adjusted to achieve iPTH < 300 pg/mL
Number of subjects: 0
Study 25955225 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not receiving denosumab)
Number of subjects: 0
Study 24074668 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic endorectal pull-through (SILEP)
Number of subjects: 58
Study 24074668 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic endorectal pull-through (CLEP)
Number of subjects: 58
Study 23070071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP), 20 mg/m × 5 days every 21 days (arm A)
Number of subjects: 326
Study 23070071 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP), 40 mg/m per week (arm B)
Number of subjects: 326
Study 19402938 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg/d
Number of subjects: 93
Study 19402938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 17705756 — intervention group
Group type: COMPARATOR
Intervention: Commercially available balloon expander (Group 1)
Number of subjects: 20
Study 17705756 — intervention group
Group type: EXPERIMENTAL
Intervention: Original dissecting balloon (Group 2)
Number of subjects: 20
Study 15165532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinstrap
Number of subjects: 15
Study 11499188 — intervention group
Group type: EXPERIMENTAL
Intervention: Video (45-minute duration)
Number of subjects: 176
Study 11499188 — intervention group
Group type: COMPARATOR
Intervention: CD-ROM (interactive)
Number of subjects: 176
Study 9683400 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-diet (34 E% fat, 10 E% polyunsaturated fat)
Number of subjects: 29
Study 9683400 — intervention group
Group type: COMPARATOR
Intervention: MUFA-diet (40 E% fat, 19 E% monounsaturated fatty acids)
Number of subjects: 29
Study 9683400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 29
Study 9683400 — intervention group
Group type: COMPARATOR
Intervention: PUFA-diet vs MUFA-diet
Number of subjects: 29
Study 7850818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 40
Study 7850818 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 40
Study 2974769 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DA2-antagonist) with ANP infusion
Number of subjects: 14
Study 2974769 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (DA2-antagonist) with head-down tilt
Number of subjects: 14
Study 2974769 — intervention group
Group type: COMPARATOR
Intervention: ANP infusion
Number of subjects: 14
Study 2974769 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 14
Study 2974769 — intervention group
Group type: COMPARATOR
Intervention: Head-down tilt
Number of subjects: 14
Study 30307945 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-calorie supplement (PCS) plus micronutrient supplement (MNS)
Number of subjects: 96
Study 30307945 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient supplement (MNS) alone
Number of subjects: 96
Study 28012242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonivamide (0.15 mg per day in 450 mL of a milk shake)
Number of subjects: 19
Study 28012242 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 19
Study 26602097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer vaccine prepared from autologous dendritic cells and uveal melanoma RNA
Number of subjects: 0
Study 23177917 — intervention group
Group type: EXPERIMENTAL
Intervention: Home use of mifepristone
Number of subjects: 301
Study 23177917 — intervention group
Group type: COMPARATOR
Intervention: Office administration of mifepristone
Number of subjects: 301
Study 21598413 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng extract (20 g/day mixed with 200 ml of water, three times/day for seven days prior and four days after exercise)
Number of subjects: 18
Study 21598413 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng extract
Number of subjects: 18
Study 18283204 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of oral glucosamine sulfate once daily
Number of subjects: 222
Study 18283204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 16571285 — intervention group
Group type: EXPERIMENTAL
Intervention: SFI pre-treatment with GP regimen
Number of subjects: 34
Study 16571285 — intervention group
Group type: EXPERIMENTAL
Intervention: SFI post-treatment with GP regimen
Number of subjects: 34
Study 16571285 — intervention group
Group type: COMPARATOR
Intervention: GP chemotherapy alone
Number of subjects: 34
Study 14763252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined kineso- and psychotherapy (Group 1, 23 patients)
Number of subjects: 41
Study 14763252 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy and explanatory psychotherapy (Group 2, 18 patients)
Number of subjects: 41
Study 10873968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for three months
Number of subjects: 71
Study 10873968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 9175690 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal lymphocytes immunization
Number of subjects: 104
Study 9175690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paternal lymphocytes immunization)
Number of subjects: 104
Study 1487626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 4
Study 1487626 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 4
Study 3942304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg epidural morphine
Number of subjects: 0
Study 3942304 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg epidural morphine
Number of subjects: 0
Study 3942304 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg epidural morphine)
Number of subjects: 0
Study 30022244 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient spa therapy
Number of subjects: 150
Study 30022244 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient spa therapy
Number of subjects: 150
Study 30022244 — intervention group
Group type: COMPARATOR
Intervention: Etodolac treatment
Number of subjects: 150
Study 26850424 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid in periarticular injection
Number of subjects: 77
Study 26850424 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid in periarticular injection
Number of subjects: 77
Study 24965739 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=126)
Number of subjects: 243
Study 24965739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment (n=117)
Number of subjects: 243
Study 24965739 — intervention group
Group type: EXPERIMENTAL
Intervention: Modic type I
Number of subjects: 243
Study 24965739 — intervention group
Group type: COMPARATOR
Intervention: Modic type II-III
Number of subjects: 243
Study 24965739 — intervention group
Group type: COMPARATOR
Intervention: Patients without Modic changes
Number of subjects: 243
Study 24965739 — intervention group
Group type: EXPERIMENTAL
Intervention: Modic size L1-S1
Number of subjects: 243
Study 23190905 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self management program (4 tailored sessions with ongoing telephone support)
Number of subjects: 165
Study 23190905 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine monitoring (2-4 structured consultations a year)
Number of subjects: 165
Study 23190905 — intervention group
Group type: COMPARATOR
Intervention: Usual care (contacts with the general practitioner at the patients' own initiative)
Number of subjects: 165
Study 20347369 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-mg monthly oral ibandronate
Number of subjects: 323
Study 18394048 — intervention group
Group type: EXPERIMENTAL
Intervention: levetiracetam (LEV) 3000 mg
Number of subjects: 38
Study 17262131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulp vitality group (n=9)
Number of subjects: 18
Study 17262131 — intervention group
Group type: COMPARATOR
Intervention: Pulp necrosis group (n=9)
Number of subjects: 18
Study 12961817 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions conducted by minimally trained community counselors (8 sessions)
Number of subjects: 366
Study 12961817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 366
Study 11034121 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-textured prototype manual toothbrush
Number of subjects: 15
Study 11034121 — intervention group
Group type: COMPARATOR
Intervention: Branded toothbrushes
Number of subjects: 15
Study 11034121 — intervention group
Group type: EXPERIMENTAL
Intervention: One of the prototype brushes
Number of subjects: 15
Study 11034121 — intervention group
Group type: EXPERIMENTAL
Intervention: One of the branded brushes
Number of subjects: 15
Study 11034121 — intervention group
Group type: COMPARATOR
Intervention: All brushes
Number of subjects: 15
Study 11034121 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional brushing method
Number of subjects: 15
Study 9373766 — intervention group
Group type: EXPERIMENTAL
Intervention: High soluble fibre diet
Number of subjects: 43
Study 9373766 — intervention group
Group type: COMPARATOR
Intervention: High insoluble fibre diet
Number of subjects: 43
Study 9373766 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP2 T54 allele
Number of subjects: 43
Study 9373766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary soluble fibre
Number of subjects: 43
Study 1383816 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of finasteride per day
Number of subjects: 895
Study 1383816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of finasteride per day
Number of subjects: 895
Study 1383816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study 3894279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Novantrone (mitoxantrone) and 5‐fluorouracil (CNF)
Number of subjects: 115
Study 3894279 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Adriamycin (doxorubicin) and 5‐fluorouracil (CAF)
Number of subjects: 115
Study 30824040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide
Number of subjects: 273
Study 30824040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus, methotrexate, and bortezomib
Number of subjects: 273
Study 30824040 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus, methotrexate, and maraviroc
Number of subjects: 273
Study 30824040 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and methotrexate (control group)
Number of subjects: 273
Study 30369135 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HPR group
Number of subjects: 13
Study 30369135 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HPR-L group
Number of subjects: 13
Study 30369135 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HPR-LM + ultrasound group
Number of subjects: 13
Study 30369135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 26931192 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (bifidobacillus and lactobacillus) administered once daily by nasogastric tube from the third day of life
Number of subjects: 714
Study 26931192 — intervention group
Group type: COMPARATOR
Intervention: No probiotics (control group)
Number of subjects: 714
Study 25304947 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 252
Study 25304947 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 252
Study 21752491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab continuous therapy
Number of subjects: 0
Study 21752491 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab after 16 weeks of placebo therapy
Number of subjects: 0
Study 19887933 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-funded trials
Number of subjects: 346
Study 19887933 — intervention group
Group type: COMPARATOR
Intervention: Non-industry funded trials
Number of subjects: 346
Study 17470079 — intervention group
Group type: EXPERIMENTAL
Intervention: Programme control/key views (PKV)
Number of subjects: 240
Study 17470079 — intervention group
Group type: COMPARATOR
Intervention: Programme control/multiple views (PMV)
Number of subjects: 240
Study 17470079 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner control/multiple views (LMV)
Number of subjects: 240
Study 17470079 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner control/key views (LKV)
Number of subjects: 240
Study 17470079 — intervention group
Group type: COMPARATOR
Intervention: No learner control/key views (SKV)
Number of subjects: 240
Study 17470079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low learner control/key views (PKV)
Number of subjects: 240
Study 15326237 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 42 days, followed by forced dose escalation to 10 mg/day)
Number of subjects: 270
Study 15326237 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 270
Study 15326237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 11273584 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)/leucovorin
Number of subjects: 2542
Study 9751447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloidal-based matrix tablet (optimized formulation)
Number of subjects: 0
Study 9751447 — intervention group
Group type: COMPARATOR
Intervention: Existing once-daily diltiazem HC1 product (Dilacor XR 240mg)
Number of subjects: 0
Study 7917729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 8 mg kg‐1 h‐1 followed by 4 mg kg‐1 h‐1 and fentanyl 15 micrograms kg‐1 (group 1)
Number of subjects: 0
Study 7917729 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 3‐6 mg and fentanyl 60 micrograms kg‐1 (group 2)
Number of subjects: 0
Study 3279089 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Methoxypsoralen (5-MOP) administered at a high oral dosage (doubled from standard dosage)
Number of subjects: 0
Study 3279089 — intervention group
Group type: COMPARATOR
Intervention: 8-Methoxypsoralen (8-MOP)
Number of subjects: 0
Study 30847444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral piracetam
Number of subjects: 100
Study 30847444 — intervention group
Group type: COMPARATOR
Intervention: Oral betahistine
Number of subjects: 100
Study 29202261 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 100
Study 29202261 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 100
Study 26551364 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite strip crown
Number of subjects: 39
Study 26551364 — intervention group
Group type: EXPERIMENTAL
Intervention: Preveneered stainless steel crown (PVSSC)
Number of subjects: 39
Study 26551364 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated primary zirconia crown
Number of subjects: 39
Study 26551364 — intervention group
Group type: COMPARATOR
Intervention: Overall satisfaction
Number of subjects: 39
Study 26551364 — intervention group
Group type: EXPERIMENTAL
Intervention: Durability of resin strip crowns
Number of subjects: 39